Maria Reyes Angeles, MD
Infectious Disease · Baton Rouge, LANPI 1194012609
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,391 of the $1,547 with a category attached, or 90.0%. It is spread thinly across 25 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $426 and has fallen 93.3% since, to $29 in 2025.
Across 49 payments — averaging $31.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$186
- Astellas Pharma US Inc$166
- Novo Nordisk$123
- Sanofi$105
- La Jolla Pharmaceutical Company$92
- Mirati Therapeutics, Inc.$76
- plus $799 from 19 others
What the payments were for
- Food & beverage$1,39190%
- Education$15510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $186 |
| Astellas Pharma US Inc | 4 | $166 |
| Novo Nordisk | 1 | $123 |
| Sanofi | 1 | $105 |
| La Jolla Pharmaceutical Company | 1 | $92 |
| Mirati Therapeutics, Inc. | 1 | $76 |
| Melinta Therapeutics, LLC | 3 | $65 |
| Supernus Pharmaceuticals, Inc. | 4 | $62 |
| Bristol Myers Squibb | 1 | $59 |
| Avanir Pharmaceuticals, Inc. | 4 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $59 |
| Amgen | 3 | $59 |
| Shionogi Inc | 2 | $58 |
| Lundbeck LLC | 3 | $52 |
| Insmed, Inc. | 3 | $51 |
| AbbVie | 2 | $50 |
| Merck | 3 | $41 |
| MDD US Operations, LLC | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 1 | $33 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $19 |
| Neurelis, Inc. | 1 | $18 |
| Biogen | 1 | $16 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$123
- MINIMED 780G$107
- SARCLISA$105
How this compares
$1,547 in reported general payments places this provider in the 60th percentile of 105 infectious disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuzyraOmadacycline Tosylate | 12 | $190,448 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 12 | $184,066 |
| Daptomycin | 55 | $82,222 |
| CeftriaxoneCeftriaxone Sodium | 38 | $5,092 |
| Azithromycin | 46 | $1,625 |
| Rifampin | 18 | $1,489 |
| Doxycycline Hyclate | 40 | $968 |
| Cefazolin Sodium | 21 | $856 |
| Cefdinir | 17 | $774 |
| Ethambutol Hcl | 15 | $672 |
| Amoxicillin | 20 | $258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Paratek Pharmaceuticals, Inc.Nuzyra | $22 | $190,44812 claims |
| Insmed, Inc.Arikayce | $51 | $184,06612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 105 infectious disease providers in Louisiana.
Other infectious disease in Baton Rouge
- Walter CampbellBaton Rouge$6K
- Waref AzmehBaton Rouge$2K
- Breanna CampbellBaton Rouge$1K
- Patrick NjokuBaton Rouge$979
- Scott AndersonBaton Rouge$937
- Shobha Rani VootukuriBaton Rouge$881
- Madeleine HeckBaton Rouge$611
- John NnadiBaton Rouge$491
- Hector Brunet RodriguezShreveport$592K
- Guillermo Padilla-PinedaShreveport$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.